BioSpace News Archive

Business

Sanofi Taps Millions Into AI Platform for Cancer Drug Discovery

The strategic collaboration entails a $180 million equity investment into Owkin and a total payment of $90 million over the next three years, in addition to milestone-based fees to be determined later.

November 18, 2021
·
2 min read
·
Vanessa Doctor, RN
Genetown

Generative Biology Pioneer Snags $370 Million to Scale Platform

Generate Biomedicines, a machine-learning protein-therapy company, raked in $370 million in a Series B financing round that will be used to advance the company’s developmental programs.

November 18, 2021
·
2 min read
·
Alex Keown
Business

Novo Nordisk Snaps Up Partner Dicerna for $3.3 Billion

Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.

November 18, 2021
·
2 min read
·
Alex Keown
FDA

COVID-19 Boosters on the Horizon for All Adults, AstraZeneca Antibody Effective

The FDA and CDC will soon decide on Pfizer-BioNTech’s request for an Emergency Use Authorization for the booster shot for their COVID-19 vaccine.

November 18, 2021
·
3 min read
·
Mark Terry
Job Trends

Foundation Lays Down $250 Million to Expand Pittsburgh Life Sciences Sites

The Richard King Mellon Foundation has awarded a $100 million gift to the University of Pittsburgh and approved a $150 million grant for Carnegie Mellon University.

November 18, 2021
·
2 min read
·
Vanessa Doctor, RN
Business

Avilar Debuts to Pioneer Extracellular Protein Degradation

Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.

November 18, 2021
·
3 min read
·
Heather McKenzie
FDA

Merck Celebrates Another Win for Blockbuster Keytruda

Merck’s Keytruda (pembrolizumab) keeps expanding the indications for which it’s approved. The company announced today that the FDA had approved the anti-PD-1 therapy for adjuvant treatment of renal cell carcinoma.

November 18, 2021
·
2 min read
·
Mark Terry
Business

BridgeBio Gets $750M on Credit to Fuel Long List of Programs

Based on BridgeBio’s current pipeline of programs, this total amount will be sufficient to carry over 30 drug development and discovery programs well into 2024.

November 18, 2021
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Novartis Investors Champing at the Bit for Action After Roche Stock Sale

Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.

November 18, 2021
·
3 min read
·
Kate Goodwin
Business

Gilead Goes All in On Arcus Option Deal Totaling $725 Million

Gilead Sciences announced it exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat.

November 18, 2021
·
3 min read
·
Mark Terry